List of Excipients in Branded Drug OXYCODONE HYDROCHLORIDE ORAL SOLUTION

Generic Drugs Containing OXYCODONE HYDROCHLORIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Aurolife Pharma LLC	oxycodone hydrochloride oral solution	13107-261	ANHYDROUS CITRIC ACID
Aurolife Pharma LLC	oxycodone hydrochloride oral solution	13107-261	FD&C RED NO. 40
Aurolife Pharma LLC	oxycodone hydrochloride oral solution	13107-261	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in OXYCODONE HYDROCHLORIDE ORAL SOLUTION?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	FD&C RED NO. 40
1	PROPYLENE GLYCOL

Last updated: August 6, 2026

Oxycodone hydrochloride oral solution is a mature, generic opioid market with limited patent barriers and high regulatory friction. Commercial opportunities are concentrated in differentiated excipient systems, preservative-free or alcohol-free presentations, pediatric and geriatric dosing usability, institutional packaging, and abuse-deterrence programs. The principal constraints are Schedule II controls, opioid quota allocation, diversion risk, product-liability exposure, and low reimbursement for undifferentiated generic liquid.

Oxycodone Hydrochloride Oral Solution Excipient Strategy and Commercial Opportunities

What is the FDA regulatory status of oxycodone hydrochloride oral solution?

Oxycodone hydrochloride oral solution is an FDA-approved immediate-release opioid analgesic. Products are generally available in low-concentration presentations such as 5 mg/5 mL and high-concentration solutions such as 20 mg/mL. The products are indicated for management of pain severe enough to require an opioid analgesic when alternatives are inadequate [1].

Oxycodone is a Schedule II controlled substance under the federal Controlled Substances Act. Manufacturers, packagers, wholesalers, pharmacies, and healthcare providers operate under Drug Enforcement Administration controls, including quota, recordkeeping, security, ordering, and distribution requirements [2].

The commercial and regulatory profile differs materially from a conventional oral liquid:

Attribute	Oxycodone hydrochloride oral solution
Dosage form	Immediate-release oral solution
Active ingredient	Oxycodone hydrochloride
FDA pathway	Abbreviated New Drug Application or 505(b)(2), depending on product and development strategy
Controlled-substance status	Schedule II
Orange Book status	Product-specific listings depend on the approved reference and applicant product
Primary generic barrier	Regulatory compliance, controlled-substance controls, manufacturing scale, and channel access
Principal technical risks	Dose measurement, taste, microbial control, preservative tolerability, excipient safety, and concentration confusion
Main commercial buyers	Retail pharmacies, hospitals, hospice providers, long-term-care facilities, specialty distributors, and government purchasers

The FDA has also approved oxycodone products with abuse-deterrent formulations, including extended-release products. Those technologies do not automatically create protection for immediate-release oxycodone oral solution. Abuse-deterrence claims must be supported by product-specific formulation and testing data [3].

What excipients are used in oxycodone hydrochloride oral solution?

Commercial oxycodone oral solutions commonly use a combination of buffering agents, sweeteners, preservatives, cosolvents or humectants, flavoring agents, and purified water. The exact composition depends on the manufacturer, concentration, container system, and approved labeling.

Typical excipient functions include:

Excipient class	Commercial function	Key development issue
Purified water	Primary vehicle	Microbial and extractables control
Sodium citrate and citric acid	pH control and buffering	Compatibility, taste, and preservative performance
Sodium benzoate	Antimicrobial preservation	Benzoate exposure, pH dependence, pediatric considerations
Sorbitol	Sweetener and bulking agent	Gastrointestinal tolerance and sugar-free positioning
Glycerin	Humectant, sweetener, and mouthfeel modifier	Viscosity and dose-pour behavior
Sodium saccharin or similar high-intensity sweetener	Taste masking	Aftertaste and patient acceptability
Flavoring agents	Oxycodone bitterness reduction	Stability, allergens, and pediatric acceptability
Alcohol or cosolvent, where used	Solubilization or preservation support	Pediatric, geriatric, institutional, and abuse-liability concerns
Chelating agent, where justified	Metal-ion control	Need for compatibility and safety justification
Suspending or thickening system	Pour control or tamper resistance	Dose uniformity and syringe delivery

An effective excipient strategy must address more than chemical stability. Oxycodone is bitter, and liquid dosing creates a direct risk of administration error. The formulation should support accurate withdrawal through oral syringes, minimize foaming, pour consistently across the shelf life, and remain acceptable after repeated opening.

A manufacturer should not assume that an excipient change is commercially meaningful by itself. The change must produce a measurable advantage in dosing accuracy, microbial robustness, palatability, packaging compatibility, stability, or institutional workflow.

Which excipient strategies create the strongest commercial opportunities?

Can alcohol-free oxycodone oral solution create a market advantage?

Alcohol-free positioning can improve access to pediatric hospitals, long-term-care facilities, hospice programs, substance-use treatment environments, and institutions with restrictive formulary policies. It can also reduce concerns involving alcohol-sensitive patients and interactions with alcohol-containing medicines.

The opportunity is strongest when alcohol-free formulation is combined with:

• Preservative optimization
• Syringe-compatible viscosity
• Improved taste masking
• Child-resistant, unit-dose packaging
• Clear concentration differentiation

Alcohol-free products may require stronger control of microbial risk and may have narrower formulation flexibility. The commercial value depends on whether the product can maintain acceptable preservative performance and shelf life without relying on ethanol or another volatile cosolvent.

Are sugar-free and low-gastrointestinal-burden formulations commercially attractive?

Sugar-free formulations are relevant to diabetic patients, institutional formularies, and consumers seeking lower excipient exposure. Sorbitol-based systems can support a sugar-free label but may cause gastrointestinal effects at higher exposure. Glycerin and high-intensity sweeteners can reduce reliance on sucrose, but they may produce mouthfeel or aftertaste problems.

The most defensible positioning is usually "sugar-free" or "low-sugar" only when supported by the complete inactive-ingredient profile and labeling review. A product should not use consumer-facing claims that imply improved tolerability without clinical or regulatory support.

Can taste masking support premium pricing?

Taste masking is one of the clearest technical opportunities because oxycodone has an inherently bitter profile. Potential approaches include:

• Flavor and sweetener combinations
• pH optimization
• Viscosity adjustment
• Ion-pairing or complexation
• Coated or encapsulated drug particles
• Multiparticulate systems dispersed in a liquid vehicle
• Metered-dose oral delivery that reduces contact with the tongue

A taste-masked product must preserve dose uniformity, chemical stability, syringe deliverability, and bioavailability. Complexation or encapsulation may also affect extraction, abuse potential, dissolution, and regulatory classification.

Taste masking has greater commercial value in pediatric or home-care markets than in hospital settings, where administration convenience and controlled dispensing may outweigh palatability.

Do preservative-free presentations have commercial value?

Preservative-free oxycodone oral solution could appeal to patients with preservative sensitivity and selected hospital or specialty-care settings. The principal challenge is microbial control after opening. A preservative-free multidose bottle may create unacceptable in-use contamination risk unless the container and dosing system provide strong protection.

More viable formats include:

• Unit-dose cups
• Single-use oral syringes
• Blow-fill-seal containers
• Short in-use periods
• Closed metered-dose systems

Preservative-free products may carry higher packaging and filling costs. The opportunity is more likely to support institutional contracts than broad retail substitution.

What formulations are protected by patents?

The basic oxycodone hydrochloride oral solution formulation is old and widely available as a generic dosage form. Core composition patents are unlikely to create a meaningful barrier for a new entrant unless the applicant develops a genuinely novel delivery system, abuse-deterrent platform, packaging configuration, or combination product.

Potentially protectable subject matter includes:

1. A specific pH-buffered composition with defined stability and impurity limits.
2. A taste-masked oxycodone liquid with specified release or sensory properties.
3. A tamper-resistant or abuse-deterrent liquid system.
4. A metered-dose pump or closed oral delivery device.
5. A unit-dose packaging system that limits diversion or dosing errors.
6. A formulation with defined preservative performance across a specified pH range.
7. A concentrated liquid designed for controlled dilution or pharmacy compounding.
8. A method of reducing administration error through concentration-specific packaging or delivery.

Patent claims directed only to routine substitutions of sweeteners, flavors, buffers, or preservatives are vulnerable to obviousness challenges. Stronger claims should connect excipient selection to unexpected stability, palatability, abuse-deterrence, dose accuracy, or manufacturing performance.

What is the Orange Book status of oxycodone hydrochloride oral solution?

FDA Orange Book listings are product-specific. The reference drug and each approved generic applicant may have different patent and exclusivity records. For an established immediate-release oral solution, the practical expectation is that market entry is driven primarily by ANDA approval rather than by licensing around a long-lived innovator patent estate [4].

A diligence review should distinguish among:

• Patent listings for immediate-release oral solution
• Patent listings for extended-release tablets
• Abuse-deterrent formulation patents
• Method-of-use patents
• Device or packaging patents
• Exclusivity attached to a particular applicant
• Patents listed for a different oxycodone dosage form

Patents covering OxyContin or other extended-release oxycodone products do not automatically block an immediate-release oral solution. The dosage form, release profile, formulation, and approved labeling determine relevance.

When does oxycodone hydrochloride oral solution lose exclusivity?

The active ingredient is long off patent, and the immediate-release oral solution market is generally characterized by generic competition. The commercial issue is therefore not a single loss-of-exclusivity date but the continuing availability of ANDA approvals and manufacturing capacity.

The principal entry scenarios are:

Entry scenario	Timing profile	Commercial effect
Additional conventional generic	After ANDA approval and any applicable exclusivity period	Price erosion and pharmacy substitution
Differentiated concentration	Subject to FDA approval and medication-error controls	May obtain niche institutional or specialty demand
Abuse-deterrent liquid	Longer development and evidence timeline	Potentially higher differentiation, higher cost
Unit-dose or metered system	Device and packaging development required	May support hospital and hospice contracts
505(b)(2) product	May require clinical or bridging evidence	More flexibility, but higher development cost
Authorized generic or licensed product	Dependent on commercial agreement	Faster market access if supply is secured

Paragraph IV litigation is possible when a new applicant challenges listed patents. For a mature immediate-release oral solution, the more material regulatory risk is often an FDA deficiency, controlled-substance supply restriction, or manufacturing inspection issue rather than a conventional patent injunction.

Which companies are challenging the market, and what is the competitive landscape?

Competition includes established generic manufacturers, specialty controlled-substance suppliers, contract manufacturers, and companies with opioid-focused distribution infrastructure. Relevant competitive capabilities include:

• DEA quota access
• Validated liquid manufacturing
• Controlled-substance security systems
• Retail pharmacy distribution
• Hospital and government contracting
• FDA inspection history
• Reliable supply during opioid quota constraints
• Ability to manage recalls and diversion monitoring

Large generic manufacturers can compete on scale and cost. Smaller specialty manufacturers can compete through concentration differentiation, unit-dose packaging, limited-distribution channels, or institutional service.

The market is structurally unfavorable to a high-cost undifferentiated entrant. A new product requires a specific purchasing rationale, such as reduced medication error, simpler inventory control, better palatability, preservative avoidance, or improved supply reliability.

What patent litigation and settlement risks affect oxycodone oral solution?

Patent litigation risk is likely to be product-specific rather than centered on the oxycodone molecule. Risk areas include:

• Listed formulation patents
• Drug-device combinations
• Abuse-deterrent technologies
• Packaging and dispensing systems
• Method-of-use claims
• Trade-secret disputes involving manufacturing processes
• ANDA litigation under the Hatch-Waxman Act

Settlement agreements may include delayed entry, supply arrangements, licensing rights, authorized-generic provisions, or restrictions tied to a specific dosage form. Any settlement should be reviewed for antitrust risk, FDA notification requirements, and whether the agreement covers only oral solution or also tablets, capsules, and extended-release products [5].

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are operational:

• Consistent potency and content uniformity
• Prevention of cross-contamination with other controlled substances
• Microbial control in aqueous systems
• Preservative effectiveness
• Container-closure integrity
• Accurate filling of low and high concentrations
• Stability after opening
• Reliable supply of certified excipients and packaging
• Controlled-substance inventory reconciliation

High-concentration oxycodone solution creates a medication-error risk because a small volume contains a substantial dose. Concentration-specific packaging, prominent labeling, oral-syringe compatibility, and restricted channel distribution can reduce that risk.

A manufacturer can seek patent protection around a complete system rather than a simple liquid formula. The strongest package may combine composition, delivery device, packaging, dosing method, and stability data.

What generic launch risks exist for oxycodone oral solution?

The principal launch risks are:

1. FDA rejection or review delay caused by formulation, labeling, bioequivalence, or container issues.
2. DEA quota limitations that prevent adequate commercial supply.
3. Pharmacy reluctance to stock a controlled liquid with diversion risk.
4. Medication errors caused by multiple concentrations.
5. Product liability tied to pediatric exposure, dosing errors, or diversion.
6. Price erosion from additional ANDA entrants.
7. Recall exposure from microbial contamination or potency failure.
8. Distribution restrictions imposed by wholesalers or manufacturers.
9. Difficulty obtaining favorable reimbursement for a differentiated product.
10. Reputational and compliance risk from opioid marketing and channel practices.

The best launch strategy is usually narrow and channel-specific. A company may target hospice, hospital discharge, long-term care, or pediatric institutions rather than compete immediately for broad retail substitution.

What licensing deals could support commercialization?

Licensing opportunities may involve:

• A formulation platform with validated taste masking
• A unit-dose or metered oral delivery device
• A controlled-substance manufacturing site
• An established opioid distribution network
• A specialty pharmacy or institutional channel
• An abuse-deterrent technology
• A contract development and manufacturing organization with DEA capacity

The commercial value of a license depends on whether the technology solves a purchasing problem. A formulation patent without manufacturing scale or channel access is unlikely to produce durable value. Conversely, a modest formulation improvement paired with reliable controlled-substance supply can support a defensible niche.

How strong is the patent estate for oxycodone hydrochloride oral solution?

The estate is weak for the unmodified active ingredient and conventional immediate-release liquid. It can become stronger for a differentiated system with:

• Narrow composition claims supported by unexpected performance
• Device claims covering dose metering
• Packaging claims limiting diversion or concentration confusion
• Abuse-deterrence claims with validated manipulation resistance
• Method claims tied to a specific administration protocol
• Manufacturing claims that produce a defined impurity or stability profile

Patent strength should be assessed claim by claim. Broad claims to routine excipient choices are likely to face validity challenges. Narrow claims supported by comparative data can have commercial value if competitors cannot design around them without losing the claimed benefit.

Key Takeaways

• Oxycodone hydrochloride oral solution is a mature Schedule II generic market.
• Conventional oral liquid formulations have limited patent protection and low barriers to technical replication.
• The best commercial opportunities are alcohol-free, sugar-free, preservative-free unit-dose, metered-dose, taste-masked, and medication-error-resistant products.
• DEA quota, controlled-substance compliance, distribution, and liability risks may be more important than patent expiration.
• Immediate-release oral solution should be analyzed separately from OxyContin and other extended-release oxycodone products.
• A differentiated product needs a defined buyer and measurable operational benefit.
• Stronger IP is more likely around delivery systems, packaging, abuse deterrence, and validated formulation performance than around routine excipient substitutions.

FAQs About Oxycodone Hydrochloride Oral Solution Commercialization

Is oxycodone oral solution a suitable 505(b)(2) opportunity?

It may be suitable when the product introduces a material formulation, delivery, packaging, or abuse-deterrent difference that cannot be efficiently pursued through a standard ANDA. A conventional copy generally has a stronger commercial rationale under the ANDA pathway.

Can a new flavor support patent protection for oxycodone liquid?

A flavor alone is unlikely to support strong patent protection. A flavor system linked to unexpected taste masking, improved adherence, stability, or reduced dose rejection may support narrower claims when supported by comparative data.

Is a 20 mg/mL oxycodone solution commercially attractive?

It can serve hospice, palliative-care, and selected institutional settings where low administration volume is important. It also creates higher concentration-confusion and diversion risks, requiring stronger labeling, packaging, and channel controls.

Can oxycodone oral solution be sold over the counter?

No. Oxycodone is a Schedule II controlled substance and requires prescription distribution under federal law [2].

Are opioid biosimilars relevant to oxycodone oral solution?

No. Oxycodone hydrochloride is a chemically synthesized small molecule, not a biologic. Biosimilar regulation does not apply. Competition proceeds through generic drug pathways and, where appropriate, 505(b)(2) applications.

References

1. U.S. Food and Drug Administration. (n.d.). Oxycodone hydrochloride oral solution prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling

3. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

5. Federal Trade Commission. (2013). Authorized generic drugs: Short-term effects and long-term impact. https://www.ftc.gov/colloquy-catalog/authorized-generic-drugs-short-term-effects-and-long-term-impact